Mindfulness-based Emotional Regulation Versus ACT in Anxiety
NCT05204264, Not applicable, Unknown, Hospital Universitario La Paz
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Mindfulness-based Emotional Regulation Versus ACT in Anxiety | ClinicalTrials.gov |
| NCT number | NCT05204264 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 128 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Hospital Universitario La Paz | ClinicalTrials.gov |
| Conditions | Anxiety | ClinicalTrials.gov |
| Interventions | Acceptance and Commitment Therapy (ACT), Mindfulness-based Emotional Regulation (MER) | ClinicalTrials.gov |
| First posted | 2022-01-24 | ClinicalTrials.gov |
| Last updated | 2022-02-07 | ClinicalTrials.gov |
Registered outcomes 30
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Trail Making Test (TMT) | Baseline | It evaluates selective/alternative visual attention by the time of execution (seconds) | ClinicalTrials.gov |
| Primary | Trail Making Test (TMT) | 2 months | It evaluates selective/alternative visual attention by the time of execution (seconds) | ClinicalTrials.gov |
| Primary | Trail Making Test (TMT) | 8 months | It evaluates selective/alternative visual attention by the time of execution (seconds) | ClinicalTrials.gov |
| Primary | Stroop Color-Word Interference Test | Baseline | It measures processing speed and visual inhibitory control by the total number of items achieved | ClinicalTrials.gov |
| Primary | Stroop Color-Word Interference Test | 2 months | It measures processing speed and visual inhibitory control by the total number of items achieved | ClinicalTrials.gov |
| Primary | Stroop Color-Word Interference Test | 8 months | It measures processing speed and visual inhibitory control by the total number of items achieved | ClinicalTrials.gov |
| Primary | Digit span subtests from the Wechsler Adult Intelligence Scale, version IV (WAIS-IV): Forward, Backward and Sequencing subtests | Baseline | It evaluates span of immediate recall and verbal working memory by the total number of items achieved and the maximum number of remembered elements | ClinicalTrials.gov |
| Primary | Digit span subtests from the Wechsler Adult Intelligence Scale, version IV (WAIS-IV): Forward, Backward and Sequencing subtests | 2 months | It evaluates span of immediate recall and verbal working memory by the total number of items achieved and the maximum number of remembered elements | ClinicalTrials.gov |
| Primary | Digit span subtests from the Wechsler Adult Intelligence Scale, version IV (WAIS-IV): Forward, Backward and Sequencing subtests | 8 months | It evaluates span of immediate recall and verbal working memory by the total number of items achieved and the maximum number of remembered elements | ClinicalTrials.gov |
| Primary | The Acceptance and Action Questionnaire-II (AAQ-II) | Baseline | It evaluates experiential avoidance and psychological inflexibility. It is a 7-item self-report instrument, rated on a 7-point Likert scale, with a total scale score ranging from 7 to 49. Higher scores indicate higher levels of experiential avoidance and psychological inflexibility | ClinicalTrials.gov |
| Primary | The Acceptance and Action Questionnaire-II (AAQ-II) | 2 months | It evaluates experiential avoidance and psychological inflexibility. It is a 7-item self-report instrument, rated on a 7-point Likert scale, with a total scale score ranging from 7 to 49. Higher scores indicate higher levels of experiential avoidance and psychological inflexibility | ClinicalTrials.gov |
| Primary | The Acceptance and Action Questionnaire-II (AAQ-II) | 8 months | It evaluates experiential avoidance and psychological inflexibility. It is a 7-item self-report instrument, rated on a 7-point Likert scale, with a total scale score ranging from 7 to 49. Higher scores indicate higher levels of experiential avoidance and psychological inflexibility | ClinicalTrials.gov |
| Primary | The Anxiety Sensitivity Index-3 (ASI-3) | Baseline | It measures concerns associated with possible negative consequences of anxiety-related symptoms in three dimensions (physical, cognitive and social). It is an 18-item self-report, rated on a 5-point Likert scale, with a total scale score (ranging from 0 to 72) and three 6-item subscales (Physical, Cognitive and Social Concerns, ranging from 0 to 24 points each). Higher scores indicate higher anxiety sensitivity | ClinicalTrials.gov |
| Primary | The Anxiety Sensitivity Index-3 (ASI-3) | 2 months | It measures concerns associated with possible negative consequences of anxiety-related symptoms in three dimensions (physical, cognitive and social). It is an 18-item self-report, rated on a 5-point Likert scale, with a total scale score (ranging from 0 to 72) and three 6-item subscales (Physical, Cognitive and Social Concerns, ranging from 0 to 24 points each). Higher scores indicate higher anxiety sensitivity | ClinicalTrials.gov |
| Primary | The Anxiety Sensitivity Index-3 (ASI-3) | 8 months | It measures concerns associated with possible negative consequences of anxiety-related symptoms in three dimensions (physical, cognitive and social). It is an 18-item self-report, rated on a 5-point Likert scale, with a total scale score (ranging from 0 to 72) and three 6-item subscales (Physical, Cognitive and Social Concerns, ranging from 0 to 24 points each). Higher scores indicate higher anxiety sensitivity | ClinicalTrials.gov |
| Secondary | The Five Facets of Mindfulness Questionnaire (FFMQ) | Baseline | It is a self-report instrument of 39 items, rated on a 5-point Likert scale, that are grouped into both a total scale score (with a mean score ranging from 1 to 5) and five specific subscales: Observing (8 items), Describing (8 items), Acting with awareness (8 items), Non-judgment (8 items), and Non-reactivity (7 items). Higher values indicate higher levels in each domain | ClinicalTrials.gov |
| Secondary | The Five Facets of Mindfulness Questionnaire (FFMQ) | 2 months | It is a self-report instrument of 39 items, rated on a 5-point Likert scale, that are grouped into both a total scale score (with a mean score ranging from 1 to 5) and five specific subscales: Observing (8 items), Describing (8 items), Acting with awareness (8 items), Non-judgment (8 items), and Non-reactivity (7 items). Higher values indicate higher levels in each domain | ClinicalTrials.gov |
| Secondary | The Five Facets of Mindfulness Questionnaire (FFMQ) | 8 months | It is a self-report instrument of 39 items, rated on a 5-point Likert scale, that are grouped into both a total scale score (with a mean score ranging from 1 to 5) and five specific subscales: Observing (8 items), Describing (8 items), Acting with awareness (8 items), Non-judgment (8 items), and Non-reactivity (7 items). Higher values indicate higher levels in each domain | ClinicalTrials.gov |
| Secondary | The Toronto Alexithymia Scale 20-item (TAS-20) | Baseline | It is a self-report instrument that measures both a global factor of alexithymia, and three specific domains: Difficulty in Identifying Feelings (7 items), Difficulty in Describing Feelings (5 items) and Externally Oriented Thinking (8 items). Items are rated on a 5-point Likert scale. The total scale score ranges between 20 and 100, with higher scores indicating greater level of alexithymia | ClinicalTrials.gov |
| Secondary | The Toronto Alexithymia Scale 20-item (TAS-20) | 2 months | It is a self-report instrument that measures both a global factor of alexithymia, and three specific domains: Difficulty in Identifying Feelings (7 items), Difficulty in Describing Feelings (5 items) and Externally Oriented Thinking (8 items). Items are rated on a 5-point Likert scale. The total scale score ranges between 20 and 100, with higher scores indicating greater level of alexithymia | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)